How Much Weight Are People Losing on Semaglutide?

Last reviewed: June 6, 2026

Last updated: June 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide has emerged as one of the most studied weight loss medications in recent history, with landmark trials demonstrating an average weight reduction of 10-22% of baseline body weight over 68 weeks of treatment. Individual results vary considerably based on genetic factors, adherence, diet, and exercise habits. Understanding what realistic outcomes look like helps set accurate expectations before starting therapy.

Clinical Trial Weight Loss Data for Semaglutide

The STEP clinical trial program enrolled over 4,500 participants with obesity or overweight with weight-related conditions. Participants receiving the highest dose of semaglutide (2.4 mg weekly) lost an average of 15.3 kg (approximately 14% of baseline body weight) at week 68 compared to placebo participants who lost 2.6 kg. Lower doses produced proportionally smaller but still clinically meaningful reductions, with the 1.7 mg dose showing approximately 11% weight loss.

These results represent some of the largest weight reductions ever documented in obesity pharmacotherapy research. The weight loss occurred progressively over the first 16-20 weeks, then stabilized with continued therapy. Notably, 85% of semaglutide-treated participants achieved at least 5% weight loss, and 69% achieved 10% or greater weight loss—thresholds associated with meaningful improvements in blood pressure, glucose control, and joint function.

Real-World Semaglutide Weight Loss Outcomes Beyond Trials

Real-world observational studies tracking semaglutide use in clinical practice show somewhat variable results compared to controlled trials. Patients in routine care settings have achieved weight reductions ranging from 8-20% of baseline body weight, with most clustering around 10-15%. Variability stems from differences in dose adherence, individual metabolic responses, dietary compliance, and whether patients combine medication with structured lifestyle modifications.

Factors influencing individual semaglutide response include age, baseline metabolic rate, insulin sensitivity status, physical activity level, and importantly, genetic variations in appetite-regulation pathways. Some patients experience rapid weight loss within the first 2-4 weeks, while others show a more gradual decline over several months. Consistent use and gradual dose escalation typically produce better outcomes than sporadic dosing or dose-jumping.

How Genetics Shape Your Personal Semaglutide Response

Semaglutide works by activating GLP-1 receptors and other peptide pathways in the brain that regulate hunger signals and satiety. Genetic variations in key genes like FTO (rs9939609), and MC4R (rs17782313) influence how strongly your body responds to these appetite-suppressing signals. A person with favorable genetic variants in GLP1R may experience more pronounced appetite reduction and weight loss, while someone with different variants might require higher doses or benefit from combination therapies.

PlexusDx Precision Peptide Genetic Test maps 14 biological pathways and 150+ genetic insights related to peptide-based weight loss therapy. This testing identifies your individual predispositions across genes affecting appetite, satiety, energy expenditure, and medication metabolism. With this genetic roadmap, your PlexusDx provider can recommend whether semaglutide injection alone is optimal for you, or whether an oral formulation, higher starting dose, or a dual-compound approach might produce faster results.

Timeline and Expectations: When Semaglutide Weight Loss Begins

Most patients notice initial appetite reduction within days of their first semaglutide injection, though measurable weight loss typically becomes apparent within 2-4 weeks as caloric intake naturally decreases. The first month often produces 2-4 pounds of weight loss as water weight and early fat loss accumulate. By weeks 8-12, monthly weight loss averages 1.5-3 pounds as the body adjusts to lower calorie intake.

The most dramatic weight loss phase typically spans weeks 12-24 as you reach stable maintenance doses and your body fully adapts to the medication's appetite-suppressing effects. By month 4-6 on semaglutide, many patients have lost 15-25 pounds. Weight loss generally continues through month 12-16, then stabilizes at a new baseline. PlexusDx compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan), allowing you to access this treatment without waiting lists or insurance denials, and your dose may need to go up—but your price won't.

How Your Genetics Relate to GLP-1 Pathways

Patients who achieve the largest weight reductions on semaglutide typically combine medication adherence with consistent dietary changes, particularly reducing ultra-processed foods and refined carbohydrates. Those who maintain or increase physical activity experience better weight loss than sedentary patients. Starting treatment at a younger age and having baseline insulin resistance (prediabetes or type 2 diabetes) also correlate with more robust responses, likely because these individuals experience greater appetite dysregulation that semaglutide corrects.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR (rs1800437) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How much weight can I realistically lose in my first month on semaglutide?

Most patients experience 2-4 pounds of weight loss in the first 4 weeks as appetite naturally decreases. Faster or slower loss is normal and depends on your starting weight, genetics, diet, and activity level. PlexusDx providers monitor your early response and adjust dosing to optimize your trajectory.

Do people keep weight off after stopping semaglutide?

Clinical follow-up data show that approximately 66% of weight loss is regained within one year after stopping semaglutide if lifestyle habits return to baseline. Patients who maintain dietary changes and exercise while on therapy are more likely to sustain weight loss long-term. Ongoing semaglutide therapy supports sustained weight reduction.

Is 10-22% weight loss realistic for someone who is mildly overweight?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

What is the cost of semaglutide treatment at PlexusDx?

PlexusDx compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan) across all three commitment tiers—your dose may increase over time for better results, but your monthly price won't. No insurance is required, and the medication is HSA/FSA eligible. Optional Precision Peptide Genetic Test costs $298.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

How does PlexusDx semaglutide differ from pharmacy semaglutide?

PlexusDx compounds semaglutide in licensed 503A compounding pharmacies and serves all 50 states without insurance requirements or membership fees. Our optional genetic testing personalizes therapy, and flat monthly pricing ($149/mo starting) means your dose can increase without price increases. You'll have direct access to PlexusDx providers who monitor your progress.

Related Reading

• Glp 1 For Losing Weight
• Zepbound For Losing Weight
• Ozempic For Losing Weight
• Mounjaro For Losing Weight

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.